These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 11113464)

  • 1. Strategies and testing methods for identifying mutagenic risks.
    MacGregor JT; Casciano D; Müller L
    Mutat Res; 2000 Nov; 455(1-2):3-20. PubMed ID: 11113464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrative test strategy for cancer hazard identification.
    Luijten M; Olthof ED; Hakkert BC; Rorije E; van der Laan JW; Woutersen RA; van Benthem J
    Crit Rev Toxicol; 2016 Aug; 46(7):615-39. PubMed ID: 27142259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term tests for defining mutagenic carcinogens.
    Waters MD; Stack HF; Jackson MA
    IARC Sci Publ; 1999; (146):499-536. PubMed ID: 10353401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the evaluation of chemicals for carcinogenicity. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment.
    Rep Health Soc Subj (Lond); 1991; 42():1-80. PubMed ID: 1763238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of the Gene-Tox Program.
    Auletta AE; Kier LD; Mitchell AD
    Prog Clin Biol Res; 1990; 340D():273-81. PubMed ID: 2371300
    [No Abstract]   [Full Text] [Related]  

  • 7. A feasibility study: Can information collected to classify for mutagenicity be informative in predicting carcinogenicity?
    Petkov PI; Patlewicz G; Schultz TW; Honma M; Todorov M; Kotov S; Dimitrov SD; Donner EM; Mekenyan OG
    Regul Toxicol Pharmacol; 2015 Jun; 72(1):17-25. PubMed ID: 25792138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of occupational carcinogens and mutagens.
    Ruder AM
    Occup Med; 1996; 11(3):487-512. PubMed ID: 8887381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prospects for a simplified and internationally harmonized approach to the detection of possible human carcinogens and mutagens.
    Ashby J
    Mutagenesis; 1986 Jan; 1(1):3-16. PubMed ID: 3325732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The parallelogram approach in studies of genotoxic effects.
    Anderson D; Sorsa M; Waters MD
    Mutat Res; 1994; 313(2-3):101-15. PubMed ID: 7523897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutagenicity and carcinogenicity of nitroarenes and their sources in the environment.
    Tokiwa H; Ohnishi Y
    Crit Rev Toxicol; 1986; 17(1):23-60. PubMed ID: 2427276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IPCS harmonization of methods for the prediction and quantification of human carcinogenic/mutagenic hazard, and for indicating the probable mechanism of action of carcinogens.
    Ashby J; Waters MD; Preston J; Adler ID; Douglas GR; Fielder R; Shelby MD; Anderson D; Sofuni T; Gopalan HN; Becking G; Sonich-Mullin C
    Mutat Res; 1996 Jun; 352(1-2):153-7. PubMed ID: 8676904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
    McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
    Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing strategies in mutagenicity and genetic toxicology: an appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes.
    Kirkland DJ; Henderson L; Marzin D; Müller L; Parry JM; Speit G; Tweats DJ; Williams GM
    Mutat Res; 2005 Dec; 588(2):88-105. PubMed ID: 16326131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
    Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
    Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The mutagenic and carcinogenic activity of chemical compounds].
    Rakitskiĭ VN; Turusov VS
    Vestn Ross Akad Med Nauk; 2005; (3):7-9. PubMed ID: 15852703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop.
    Kirkland D; Pfuhler S; Tweats D; Aardema M; Corvi R; Darroudi F; Elhajouji A; Glatt H; Hastwell P; Hayashi M; Kasper P; Kirchner S; Lynch A; Marzin D; Maurici D; Meunier JR; Müller L; Nohynek G; Parry J; Parry E; Thybaud V; Tice R; van Benthem J; Vanparys P; White P
    Mutat Res; 2007 Mar; 628(1):31-55. PubMed ID: 17293159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precedents or possibilities: which should guide the harmonization of mutagenicity test protocols and carcinogen prediction strategies?
    Ashby J
    Mutat Res; 1993 Feb; 298(4):291-5. PubMed ID: 7678166
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutagenicity in drug development: interpretation and significance of test results.
    Clive D
    Regul Toxicol Pharmacol; 1985 Mar; 5(1):79-100. PubMed ID: 3991935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on the US EPA recommendation for genotoxicity guidelines on chemicals.
    Ishidate M
    Mutat Res; 1992 Aug; 272(1):79-80. PubMed ID: 1380121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.